Iovance Biotherapeutics (IOVA) Shareholder Investigation

Shamis & Gentile, P.A. is investigating potential shareholder claims on behalf of Iovance Biotherapeutics, Inc. (“Iovance Biotherapeutics” or the “Company”) (NASDAQ: IOVA) against certain of its directors and officers for alleged breaches of fiduciary duty and other violations of law. Concerned shareholders are advised to contact the firm now.

The investigation follows the filing of a class action complaint against Iovance Biotherapeutics, which alleges that the Company’s directors and officers made materially false and misleading statements and failed to disclose adverse information about forecasting, manufacturing, and commercialization functions following the launch of Amtagvi (lifileucel). On July 24, 2024, Iovance announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. According to the class action lawsuit, management repeatedly reaffirmed overly optimistic revenue guidance while downplaying known production and adoption challenges.

In its August 8, 2024 quarterly release, the Company projected $450 to $475 million in 2025 revenue and described “robust growth” and “strong demand.” Executives said growth would come from “scale up in existing and new ATCs” and “community referral networks.” The same $450 to $475 million guidance was reiterated in November 2024 and February 2025, as management continued to emphasize significant year over year growth while describing iCTC manufacturing as operating “at full volume.”

On May 8, 2025, Iovance reduced its forecast by more than 40% to $250 to $300 million for 2025, citing “limited production starts,” “lower Proleukin sales,” and a “variable pace” of patient treatment.

Following these disclosures, shares fell 44.8%, from $3.17 to $1.75, resulting in a significant loss of market capitalization.

If you have held Iovance Biotherapeutics (NASDAQ: IOVA) stock since at least May 2024, you may be able to seek corporate reforms, the return of funds back to the Company, and a court-approved incentive award for you, all at absolutely no cost.

Shamis & Gentile, P.A. stands out as an advocate for shareholders seeking corporate accountability and governance reforms. The firm is committed to pursuing shareholder actions that benefit companies and their shareholders by recovering damages and implementing meaningful corporate governance improvements. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including shareholder actions, class actions and complex commercial litigation.

Attorney advertising. Prior results do not guarantee similar outcomes.